Florida Cancer Specialists & Research Institute Television Commercial Recognized with Silver ADDY® Award
A television commercial produced by Florida Cancer Specialists & Research Institute, LLC (FCS) has been recognized with a Silver ADDY® by the American Advertising Awards, which honors excellence in advertising as judged by creative industry professionals around the world.
Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.
Patients With HR+/HER2- Advanced Breast Cancer May Reduce Ribociclib Dose Without Jeopardizing Outcomes
Reducing ribociclib dosing by 200 mg or 400 mg did not affect overall survival in patients with hormone receptor–positive, HER2-negative, advanced breast cancer.
Pollack Discusses Ongoing Research for Patients With Refractory mCRC and Other Hard-to-Treat GI Malignancies
Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
Nivolumab/Cabozantinib Shows Continued Benefit In Frontline Treatment of RCC
Goodman Highlights Potential Benefit of SBRT in Locally Advanced Pancreatic Cancer
